Anti-PD-1/PD-L1 therapies have demonstrated prominent clinical effects in the treatment of non-small cell lung cancer (NSCLC). However, limited understanding of the regulatory mechanisms of PD-L1 has become one of the biggest challenges for further improving efficacy. In this study, we observed that in wild-type EFGR cell lines A549 and H460, the ubiquitin ligases Cbl-b and c-Cbl inhibit PD-L1 by inactivating STAT, AKT, and ERK signaling. MiR-181a and miR-940 were screened and validated to target Cbl-b and c-Cbl, respectively. Furthermore, in NSCLC tissues, the expression of Cbl-b/ c-Cbl is negatively correlated with PD-L1 expression. Taken together, these findings indicated a new regulatory mechanism for PD-L1 in wild-type EGFR NSCLC cell lines by Cbl-b and c-Cbl.
Lung cancer remains one of the leading causes of cancer death worldwide [1] . Although developments in chemotherapy and molecular-based therapies have dramatically improved the clinical outcome of nonsmall cell lung cancer (NSCLC) [2] [3] [4] , the poor overall survival rate has directed the attention of medical researchers to the potential of immunotherapy. Anti-PD-1/PD-L1 antibodies have showed durable responses in the treatment of NSCLC [5] [6] [7] [8] , however, only a limited subset of patients has benefited thus far [9] . Identification of biomarkers that determine therapy responsiveness is a focus of current research and PD-L1 expression has been proposed as one such biomarker [10, 11] . Thus, it is of great value to fully understand the regulatory mechanisms of PD-L1.
Among the driver genes in lung cancer, it is acknowledged that EGFR is the most important and well-studied one. While tyrosine kinase inhibitors have transformed the treatment of patients whose tumors harbor activating mutations in EGFR [3] , specific therapeutic strategies for wild-type EGFR patients are limited and poorly developed. Recently, several phase III clinical trials have revealed anti-PD-1/PD-L1 inhibitors are more effective in patients with wild-type EGFR compared with those harboring EGFR mutations [5, 12, 13] . Moreover, it was reported that genetic alterations in tumors are correlated with PD-L1 regulation. Some studies demonstrated EGFR mutation induced high PD-L1 expression via downstream pathways in NSCLC [14] [15] [16] . However, the underlying molecular mechanisms in wild-type EGFR tumors are largely unknown. Thus, extensive investigations of PD-L1 expression in this subtype are crucial for effective screening of patients for immunotherapy.
The PD-1/PD-L1 pathway is known to play an important role in the immune system. Engagement of PD-L1 with PD-1 transmits a signal that inhibits the activation and proliferation of T cells and secretion of IL-2, IFN and IL-10 [16] . Following the interaction of PD-L1 with PD-1, downmodulation of the T-cell receptor occurs through upregulation of the E3 ubiquitin ligase Cbl-b [17] . Both c-Cbl and Cbl-b are membranes of the Cbl protein family and are well-known critical negative regulators of lymphocyte development, functioning through their targeting of key protein tyrosine kinases [18] . In addition to T-cell-mediated effects, our previous studies showed that Cbl-b and c-Cbl in tumor cells regulate the proliferation, migration and drug sensitivity of cancer cells by downregulating target tyrosine kinase receptors and growth signaling proteins [19] [20] [21] . Moreover, these signals were also involved in PD-L1 expression. Although there is no direct evidence as yet, these data imply that the Cbl family protein might also participate in the regulation of PD-L1 in NSCLC.
In our current study, we demonstrated that the ubiquitin ligases Cbl-b and c-Cbl downregulated PD-L1 expression through the STAT, AKT, and ERK pathways in wild-type EGFR lung cancer cells. Furthermore, miR-181a and miR-940 induced PD-L1 by targeting Cbl-b and c-Cbl.
Materials and methods

Cell culture
Human NSCLC cell lines A549 and H460 were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Both the cell lines were cultured in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and antibiotics (100 UÁmL À1 , penicillin and 100 mgÁmL À1 , streptomycin).
The cells were maintained in an atmosphere of 95% air and 5% CO 2 at 37°C.
Western blot
Western blot was performed as previously described [19] . Briefly, the membranes were incubated with indicated primary antibodies at 4°C overnight and then further incubated with secondary antibodies at room temperature for 30 min. 
MicroRNA microarray for miRNAs
A549 and H460 cells were cultured and total RNA was isolated. The miRNA expression profiles for each total RNA sample were analyzed using GeneChip miRNA Array (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's instructions by Gene Tech Biotechnology Company (Shanghai, China). In brief, total RNA (1 lg) was extracted and labeled with a FlashTag Biotin RNA Labeling kit (Genisphere, Hatfield, PA, USA). Then the labeled RNA was injected onto the microarrays and incubated at 48°C for 16 h. After washing and staining, the signals were obtained using a GeneChip Scanner 3000 7G (Affymetrix). Data were normalized using the RMA algorithm.
Transient transfection of plasmid constructs
H460 cells were transfected using Lipofectamine 2000 with pcDNA 3.1 plasmid containing Cbl-b or c-Cbl or pcDNA3.1 vector alone. After 72 h, western blot experiments were conducted to verify gene overexpression efficiency.
RNA isolation and real-time PCR
The isolation and reverse transcription of RNA was performed as previously described [21] . Comparative cycle threshold (C t ) method was used to calculate relative expression of miR-181a and miR-940 and the expression of U6 small nuclear RNA was used as reference. The forward primers for miR-181a and miR-940 were as follows: 5 0 -AACATTCAACGCTGTCGGTGGT-3 0 and 5 0 -AAGGT TTAGCCGCTCCCCAAA-3 0 , respectively. The PCR conditions were 10 min at 95°C, followed by 45 cycles at 95°C for 15 s and 58°C for 34 s.
Patients and immunohistochemistry (IHC)
This study was approved by The Human Ethics Review Committee of the First Hospital of China Medical University. One hundred and thirty-three primary NSCLC samples were enrolled in the study. All specimens were regularly fixed with formaldehyde, embedded in paraffin sections, and prepared with a thickness of 4 lm. Immunohistochemistry (IHC) staining procedure was performed as previously described [21] . All specimens were examined independently by two experienced pathologists and staining intensity and proportion of membranous and/or cytoplasmic staining in tumor cells were assessed. The staining intensity was defined as 0 = negative, 1 = weak, 2 = intermediate, and 3 = strong. 
Statistical analysis
The experimental data were present as the mean AE standard deviation (SD) and representative results were from three independent experiments. Statistical comparisons were calculated by Student's t-test. Spearman correlation coefficient was obtained to examine the relationships between PD-L1 and Cbl-b/c-Cbl expression. Survival analysis was performed by Kaplan-Meier (KM) method and assessed by log-rank test. Statistical analyses were carried out using SPSS 16.0 (Chicago, IL, USA) and P < 0.05 was considered to be statistically significant.
Results
Expression of PD-L1 and oncogenic activation of STAT3/AKT/ERK signaling in wild-type EGFR NSCLC cell lines
To reveal the regulatory mechanism of PD-L1, we first analyzed the basal levels of PD-L1 in A549 and H460 cell lines, both of which have wild-type EGFR status. As shown in Fig. 1A ,B, compared with A549, PD-L1 expression on the cell surface of H460 was significantly higher, which was in accordance with the protein levels detected by western blot (Fig. 1C) . Meanwhile, H460 cells also demonstrated higher p-STAT3, p-AKT, and p-ERK levels, which positively correlated with PD-L1 expression (Fig. 1D) . These results indicate that STAT3, AKT, and ERK signaling may be involved in the regulation of the PD-L1 in wild-type EGFR NSCLC cell lines.
STAT3/AKT/ERK signaling upregulated PD-L1 expression
To explore the potential effect of STAT3/AKT/ERK signaling on PD-L1 expression, we first inhibited p-STAT3, p-AKT, and p-ERK by inhibitors. The results showed that treatment of H460 cells with 2 lM STAT-TIC (STAT3 inhibitor), 25 lM LY294002 (PI3K/AKT inhibitor), and 20 lM PD98059 (ERK inhibitor) for 24 and 48 h significantly decreased PD-L1 expression both at protein and cell surface level compared with the control groups ( Fig. 2A-D , P < 0.05). Then, we employed two different small interfering RNAs (siRNAs) to knock down STAT3, AKT and ERK expression, respectively. As expected, both the siRNAs knocked down expression of their target proteins with subsequent downregulation of PD-L1 in H460 cells ( Fig. 2E -H, P < 0.05).
In conclusion, these results demonstrated that the activation of the STAT, AKT, and ERK pathways upregulated PD-L1 expression.
Cbl-b and c-Cbl downregulated PD-L1 expression by inhibiting STAT3/AKT/ERK signaling
As STAT, AKT, and ERK signaling is responsible for PD-L1 expression and our previous studies demonstrated that E3 ubiquitin ligase Cbl family proteins mediate their ubiquitination, it is feasible that Cbl family proteins regulate PD-L1 expression. Therefore, we assessed the expression of Cbl-b and c-Cbl in A549 and H460 cells. A549 cells expressed significantly higher levels of Cbl-b and c-Cbl than that of H460, which was negatively associated with PD-L1 (Fig. 3A) .
To examine the effect of Cbl-b and c-Cbl on PD-L1 expression, A549 cells were transiently transfected with siRNAs targeting Cbl-b and c-Cbl. Cbl-b or c-Cbl knockdown increased the expression of p-STAT3, p-AKT, and p-ERK, as well as PD-L1 compared with the negative control group (Fig. 3B) . Interestingly, after single knockdown of Cbl-b or c-Cbl, the other slightly increased because of their complimentary mode-of-action to each other. Thus, we simultaneously knocked down Cbl-b and c-Cbl; the addition of two siRNAs significantly increased the PD-L1 expression in A549 cells (Fig. 3D, left) . Furthermore, overexpression of Cbl-b and c-Cbl in H460 cells significantly inhibited the activation of p-STAT3, p-AKT, and p-ERK and downregulated PD-L1 levels compared with the empty vector group (Fig. 3C,D, right) .
MiR-181a and miR-940 inhibited Cbl-b and c-Cbl and upregulated PD-L1
Quantitative PCR analysis showed the mRNA levels of Cbl-b and c-Cbl were opposite to the respective protein levels (Fig. 4A) , suggesting post-translational modifications are involved in regulating Cbl-b and c-Cbl expression. Given that microRNAs (miRNAs) silence mRNAs by interfering with their translation, a microarray analysis was performed (Fig. 4B) . We identified miRNAs that were significantly differentially expressed (more than four times) and could potentially targeting Cbl-b and c-Cbl using miRDB predictions (http://www.mirdb.org/miRDB/). The expression levels of these miRNAs were quantified as fold-change normalized to U6 by real-time PCR. Among them, miR181a and miR-940 were significantly upregulated in H460 cells compared with A549 cells (Fig. 4C ). Other miRNAs screened were either inconsistent with the chip, or the reproducibility of the results was poor. Putative miR-181a and miR-940 sequences were found in the 3 0 UTR of the Cbl-b and c-Cbl transcripts, respectively (Fig. 4D) . Next, A549 cells were transfected with mimics of miR-181a/miR-940 or negative control; we observed downregulation of Cbl-b and cCbl and upregulation of p-STAT3, p-AKT, and p-ERK protein and then PD-L1 expression. When endogenous miR-181a or miR-940 was inhibited in H460 cells using inhibitors, Cbl-b and c-Cbl was increased in parallel with decreased expression of p-STAT3, p-AKT, p-ERK protein, and PD-L1 (Fig. 4E) . Next, a dual luciferase reporter assay was performed to further validate Cbl-b as the target gene for miR-181a and c-Cbl for miR-940. When A549 cells were transfected with miR-181a or miR-940 mimics, the luciferase activity was decreased significantly (P < 0.05). Downregulation of luciferase activity was not observed in the mutation groups (Fig. 4F) . These results indicate that miR-181a and miR-940 indirectly upregulate PD-L1 through inhibition of Cbl-b and cCbl and induction of the STAT3/AKT/ERK signaling. c-Cbl expression were associated with survival time; patients with low PD-L1, high Cbl-b, and high c-Cbl expression showed prolonged overall survival (Fig. 5B -D, all P < 0.05).
Association between Cbl-b/c-Cbl and PD-L1 and prognosis in NSCLC patients
Discussion
The PD-1/PD-L1 pathway plays a vital role in the balance of the immune system as an inhibitory signal [16] . PD-L1 is overexpressed in multiple tumor types including NSCLC [14, 22] , and is observed to contribute to immune escape via its interaction with PD-1. Considering the critical functions of PD-L1 in immune suppression and immunotherapy, thorough identification of the regulatory mechanisms is essential to improve the efficacy and prognosis of NSCLC patients. In this study, we demonstrated a potential role of Cbl-b and c-Cbl in inhibition of PD-L1 expression in wild-type EGFR NSCLC cells and revealed the underlying mechanisms involved including STAT3, AKT, and ERK signaling and post-translational modification of Cbl-b and c-Cbl by miR-181a and miR-940. Furthermore, we found that in NSCLC tumor tissues, the expression statuses of Cbl-b and c-Cbl were negatively correlated with PD-L1 expression. It is widely accepted that intrinsic and extrinsic immune resistance modalities are two mechanisms for the regulation of PD-L1 by tumor cells. While PD-L1 is upregulated in response to multiple inflammatory factors as a dynamic biomarker of active inflammation [23, 24] , oncogene activation also induced constitutive PD-L1 overexpression [25, 26] . Emerging evidence suggests that coexistence of driver mutations in NSCLC is frequently associated with higher PD-L1 expression. Previous studies have shown EGFR mutations [14] [15] [16] , ALK rearrangements [27, 28] , and KRAS mutations [29] were positively correlated with PD-L1 expression. However, the regulatory mechanism in wild-type EGFR tumors is still unknown. The better response of wildtype EGFR NSCLC to anti-PD-1 treatment drew our attention to this field. Thus, in our study, we selected A549 and H460 cell lines, which are both wild-type for EGFR but have different levels of PD-L1 expression. To explore the potential regulatory mechanisms of higher PD-L1 levels in H460 cells, we examined the downstream signaling pathways, as previously reported [15, 26, 29] ; the results showed PD-L1 upregulation was associated with the activation of STAT3, AKT, and ERK. By inhibiting p-STAT3, p-AKT, and p-ERK, PD-L1 was significantly decreased. All these results indicate that STAT3/AKT/ERK signaling plays a critical role in regulation of PD-L1 expression independent of EGFR mutation. In addition, these signals were previously demonstrated to be involved in the proliferation, invasion, and drug resistance of tumor cells. Here, our data solidly supports that the activation of these oncogenic pathways induced PD-L1 overexpression and that in turn played a critical role in immune escape.
Although multiple studies have focused on PD-L1 expression and its function in NSCLC, we are the first to explore its expression and relationship with Cbl family proteins in NSCLC cells and patients. Cbl-b and cCbl are two members of the Cbl family, which are key regulatory factors in maintaining immune system homeostasis and autoimmune -tolerance [18, 30] . Our previous studies have reported that Cbl family proteins are involved in many aspects of tumors development [19] [20] [21] . The results in this study indicated that Cbl-b and c-Cbl in NSCLC cells inhibited PD-L1 by downregulation of p-STAT3, p-AKT, and p-ERK pathways. Furthermore, in NSCLC samples, Cbl-b/c-Cbl and PD-L1 were negatively correlated and they all associated with overall survival. Taken together, these results suggest the differential regulation and correlation between Cbl family proteins and PD-L1 in different cellular processes and cell types. In the process of T-cell activation, upregulation of Cbl-b was secondary to PD-1/PD-L1 signals, while in tumor cells, Cbl-b and cCbl conversely inhibited PD-L1, which in turn could relieve the immune suppression. These results revealed that a new role of Cbl proteins in immune responses.
We are the first to show that Cbl-b/c-Cbl inhibit PD-L1 expression in a miR-181a/Cbl-b and miR-940/ c-Cbl axis. It is widely recognized that miRNAs are involved in the biological behavior of tumor cells by regulating their target genes. MiR-181a is one of the members of the miR-181 family [31] which are essential for diverse cellular processes. Several studies have pointed that expression of miR-181a is downregulated in breast cancer and appeared to exerts anti-oncogenic roles by preventing metastasis and promoting apoptosis [32, 33] . Nonetheless, others have suggested that overexpression of miR-181a was associated with tumor aggressiveness. It has been previously reported that miR-181a is involved in breast cancer resistance and metastasis through downstream STAT3 molecules [34] . Li et al. reported miR-181a also targets PTEN to promote liver metastasis of colon cancer [35] . Studies before have also revealed the functions of miR-940 in different diseases. In prostate cancer, miR-940 inhibits metastasis by targeting MIEN1 protein [36] . Moreover, researches revealed that aberrant miR-940 expression was involved in the proliferation and invasion of pancreatic carcinoma [37, 38] . However, the functions and target genes of miR-181a and miR-940 are still unclear in NSCLC. In this study, we first investigated whether miR-181a and miR-940 could potentially regulate Cblb and c-Cbl using bioinformatics tools and through a series of experiments to confirm this speculation. In summary, this study provided evidence that miR181a and miR-940 upregulate PD-L1 expression by 
